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Background: Differential expression and secretion of alpha-actinin 
4 (ACTN4) in the lung cancer cell lines CL1-0 and CL1-5 have 
been reported in previous proteomic studies. The aim of this study 
is to investigate the functional properties of the ACTN4 protein in 
non–small-cell lung cancer (NSCLC) cells and evaluate its clinical 
importance.
Methods: We used RNA interference to knock down and overex-
press ACTN4 protein to evaluate the effects of this intervention on 
cancer cell invasion and migration, as well as on microscopic cellular 
morphology. Furthermore, we examined by immunohistochemistry 
the expression of ACTN4 protein in tissue samples at different stages 
of lung cancerand compared the protein levels of ACTN4 in blood 
plasma samples from patients with histologically confirmed lung 
cancer and healthy controls.
Results: CL1-5 cell motility was significantly suppressed by the 
knockdown of ACTN4 protein. The morphology of CL1-5 cells 
changed from a predominantly mesenchymal-like shape into a globu-
lar shape in response to ACTN4 protein knockdown. A quantitative 
immunohistochemical assessment of lung cancer tissues revealed 
that ACTN4 protein level was considerably higher in cancerous tis-
sues than in the adjacent normal ones, and the area under the receiver 
operating characteristic curve was 0.736 (p < 0.001). According to an 
enzyme-linked immunosorbent assay, the plasma levels of ACTN4 
protein were significantly different between cancer patients and 
healthy controls, and the areas under the receiver operating charac-
teristic curves were 0.828 and 0.909, respectively, for two indepen-
dent cohorts (p < 0.001).
Conclusions: We demonstrate that the knockdown of ACTN4 pro-
tein inhibited cell invasion and migration. These results suggest that 
ACTN4 is associated with lung cancer cell motility. Thus, the level 
of ACTN4 in cancerous tissue and plasma is related to the presence 
of lung cancer.
Key Words: ACTN4; non–small-cell lung cancers; CL1-0 and 
CL1-5 cell lines; siRNA
(J Thorac Oncol. 2015;10: 286–301)
Lung cancer is the most common cancer in the world and has been the malignancy with the highest mortality for sev-
eral decades. Non–small-cell lung cancer (NSCLC) accounts 
for approximately 85% of all lung cancers.1 Early NSCLC 
is treated with surgery, with survival rates of 35% to 85% 
depending on tumor size and stage.2 However, most NSCLC 
patients are asymptomatic, and cancers are detected late. 
Moreover, the overall 5-year survival rates of patients with 
NSCLC are determined by the cancer stages, ranging from 
49% for stage IA to only 1% for stage IV.3
The exceedingly low survival rates and increased mor-
tality from cancers are believed to be due to cancer metasta-
sis.4 Numerous reports have shown that cancer cell–secreted 
proteins are related to cancer metastasis; these factors aid in 
cell migration/invasion and the modulation of the microenvi-
ronment.5,6 From previous comparative secretomic analyses of 
two NSCLC cell lines, CL1-0 cells (which have a low invasive 
ability) and CL1-5 cells (which have a high invasive ability),7 
ACTN4 protein has been identified as a relatively abundant 
secreted candidate protein in CL1-5 cells.8–10
ACTN4 protein is a member of the cytoskeletal protein 
family; it binds to actin filaments to preserve cytoskeletal struc-
ture and cell morphology.11–13 ACTN4 is expressed in nonmuscle 
cells and is commonly associated with focal adhesion contacts 
and migrating cells.14 The structure of the ACTN4 protein con-
tains conserved functional domains, including an N-terminal 
actin-binding domain with two highly conserved calponin 
homology domains, a central domain consisting of four spectrin 
repeats, and a calmodulin-like domain in the C-terminus.14,15
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Cancer cell migration in the extracellular matrix (ECM) 
requires that cell protrusions of lamellipodia, pseudopodia, or 
filopodia are formed at the leading edge of the cancer cell. 
The protrusion of these cells requires actin polymerization 
and rearrangement.16,17 Following the formation of protrusions 
in cancer cell membranes, the cancer cells develop new focal 
adhesion complexes and secrete proteins for local ECM pro-
teolysis. Eventually, the cancer cells release their contacts at 
the rear and initiate migration.18 Therefore, ACTN4 may play 
an important role in cancer cell motility and may modulate 
cytoskeletal organization by cross-linking actin filaments.
In the current study, we utilized small interfering RNA 
(siRNA)–mediated ACTN4 protein knockdown, combined 
with migration and invasion assays, to examine the function 
of ACTN4 in CL1-5 cells. To investigate whether ACTN4 has 
the potential to be a useful biomarker for lung cancer, a tissue 
microarray (TMA) was used to determine the expression of 
ACTN4 protein at different stages of cancer in lung tissues and 
in adjacent normal tissues. In addition, a sandwich enzyme-
linked immunosorbent assay (ELISA) was applied to measure 
the plasma concentration of ACTN4 protein in patients at dif-
ferent stages of lung cancer and in healthy controls.
MATERIALS AND METHODS
Cell Lines
The poorly differentiated CL1-0 and CL1-5 cells were 
provided by Dr. P.C. Yang (Department of Internal Medicine, 
National Taiwan University Hospital, Taiwan). The main-
tenance of CL1-0 and CL1-5 cells, including standardiza-
tion of the media and growth conditions, was performed as 
described previously.7,9 The lung cancer cell line A549 was 
purchased from the American Type Culture Collection and 
maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum (FBS) (Gibco BRL, Life 
Technologies, Carlsbad, CA) and 1% penicillin (Invitrogen, 
Life Technologies, Carlsbad, CA).
Conditioned Medium and Cell Extracts
CL1-0 and CL1-5 cells were cultured at 37°C with 
5% carbon dioxide in RPMI-1640 medium supplemented 
with 10% FBS. The cells were grown to 70% confluence and 
washed four times with serum-free medium before they were 
incubated in serum-free medium for 24 hours. The collected 
conditioned medium (CM) was concentrated by centrifugation 
in Amicon Ultra-15 tubes (3-kDa cutoff; Millipore, Billerica, 
MA). The cell extracts (CEs) were also collected in parallel 
as follows. The cultured cells were washed with phosphate-
buffered saline and trypsinized (Biowest, Nuaillé, France). 
The collected cells were resuspended in distilled water and 
lysed by microsonication at 4°C. The suspension was centri-
fuged to remove any cell debris. The Bradford assay (Bio-Rad, 
Hercules, CA) was used to determine the total protein concen-
tration in the prepared CM and CE samples.
Protein Electrophoresis and Western Blot
Aliquots (10 μg) of protein from the CM and CE 
samples were individually separated on NuPAGE 4%–12% 
Bis–Tris gels (Invitrogen) using a Novex Mini-Cell electro-
phoresis system (Invitrogen). The proteins were transferred 
to an iBlot polyvinylidene fluoride membrane (Invitrogen) 
according to the manufacturer’s protocol. The transferred 
membrane was blocked in nonfat milk solution. The mem-
branes were separately probed with an anti-ACTN4 antibody 
(1:1000; Epitomics, Burlingame, CA), an anti-PGAM1 anti-
body (1:1000; Epitomics), or an anti-actin antibody (1:1000; 
GeneTex, San Antonio, TX). The membranes were then 
washed with Tris-buffered saline and Tween-20 and incubated 
with the appropriate secondary antibodies conjugated to horse-
radish peroxidase (HRP) (1:100,000; Sigma-Aldrich). The 
membranes were washed and developed using an enhanced 
chemiluminescence reagent (PerkinElmer, Waltham, MA) 
and photographed using a UVP BioSpectrum imaging system 
(UVP, Upland, CA).
Small Interfering RNA-–Mediated 
ACTN4 Protein Knockdown
The two siRNAs targeting ACTN4 protein were 
purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA) and Life Technologies (Carlsbad, CA). 
The sequences for ACTN4 siRNA knockdown com-
prised two pools of RNA sequences; pool I of ACTN4 
siRNA contained (1) 5′-CAGAGCUGAUUGAGUAUGA-3′, 
(2) 5′-CACUCUGUAUCUAUGCAAA-3′, and (3)  5′-CUGG 
UCUGGUAAAUAUGUA-3′ (Santa Cruz); and pool II of 
ACTN4 siRNAs sequences contained (1) 5′-GACCAGAGCU 
GAUUGAGUT-3′ and (2) 5′-CGCAAAUCAUCAACUCC 
AA-3′ (Life Technologies). The siRNA transfection process 
was performed using the different cell lines according to the 
manufacturer’s instructions. Briefly, the CL1-5 cells (2 × 105 
cells) were seeded in a six-well culture plate. For each trans-
fection, the final siRNA targeting ACTN4 (30 pM siRNA) or a 
scrambled control siRNA was added along with siRNA trans-
fection reagent (Santa Cruz). The reactions were mixed gently, 
overlaid onto the cells, and incubated for 24–48 hours.
Transient Transfection for ACTN4 Protein 
Overexpresssion in CL1-0 Cells
ACTN4 gene overexpression in CL1-0 cells was achieved 
through transfection with human ACTN4 DNA vector (Cat No. 
RC202873; OriGene Technologies, Inc., Rockville, MD) and 
pSV-β-Galactosidase control vector (Promega, MA) using the 
Fugene6 transfection reagent according to the manufacturer’s 
instructions (Promega). The CL1-0 cells (1 × 105 cells) were 
seeded in a six-well culture plate and grown to 50%–70% 
confluence. Fugene 6 transfection reagent (3 μl) was directly 
added into serum-free medium (97 μl), and then ACTN4 
DNA vector (1 μg) was added into the prepared transfection 
medium for each ACTN4 DNA vector transfection. The trans-
fection reagent and DNA mixture was added into cultured 
cells. The reactions were incubated at 37°C in the presence 
of 5% carbon dioxide for 48 hours. The collected cells were 
washed in distilled water and lysed by microsonication at 4°C. 
The suspension was centrifuged to remove any cell debris. 
The Bradford assay was used to determine the total protein 
concentration. Total proteins (20 μg) from the collected CEs 
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of CL1-0 cells transfected with ACTN4 DNA vector or con-
trol vector were individually separated on NuPAGE 4%–12% 
Bis–Tris gels and Western blotting was performed.
3-[4,5-Dimethylthiazol-2-yl]-2,5-
Diphenyltetrazolium Bromide Assay
The indicated cells (1 × 103 cells per well) were seeded 
in a 96-well plate and treated with either ACTN4 siRNA or a 
scrambled control for 24 hours. 3-[4,5-Dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT; 10 μl of a 500 μg/ml 
solution) was added to each well and incubated for 2 hours. After 
incubation, to each well was added 100 μl detergent reagent 
(10% Triton X-100 in isopropanol) and incubated at room tem-
perature in the dark for 2 hours. The viability of each cell line 
was monitored every 24 hours, for 72 hours. The cells were then 
lysed with dimethyl sulfoxide. A microplate photometer was 
used to measure the absorbance at 595 nm (Multiskan EX micro-
plate reader; Thermo Fisher Scientific Ltd., Waltham, MA). The 
results were obtained by culturing the cells under each condition 
in six different wells in three independent experiments.
Bromodeoxyuridine Assay
Bromodeoxyuridine (BrdU) assays to measure cell pro-
liferation were performed according to the manufacturer’s 
instructions (Roche Applied Science, Mannheim, Germany). 
Briefly, lung cancer cells (1 × 103 cells per well) were seeded 
in each well of a 96-well plate. The BrdU reagent (10 μl of 
100 μM BrdU) was added to each well and incubated for 
2 hours at 37°C. After prepared cells were fixed in FixDant 
(200 μl per well) for 30 minutes and washed, 100 μl of anti-
BrdU antibody conjugated with HRP (100-fold dilution) 
was individually added to each well. The developer substrate 
(100 μl of 1.25 mM tetra-methylbenzidine [TMB] per well) 
was then added, followed by the stop solution (25 μl of 1M 
H
2
SO
4
). The cell growth within each group was checked 
every 24 hours for 72 hours. A microplate photometer was 
used to measure the absorbance at 450 nm (Multiskan EX 
microplate reader). The results were obtained by culturing 
the cells under each condition in six different wells in three 
independent experiments.
Transwell Migration and 
Matrigel Invasion Assays
Transwell membranes (8-μm pore size; BD Biosciences, 
San Jose, CA) were used for the migration assay. Lung cancer 
cells (1 × 105) in serum-free RPMI-1640 medium were tryp-
sinized, washed, and loaded into each upper well. The lower 
chambers were filled with medium containing 10% FBS to 
induce cell migration. Transwell membranes (8-μm pore size; 
BD Biosciences) coated with Matrigel basement membrane 
matrix (BD Biosciences) were used for the cell invasion assay. 
After 24 hours of incubation, the filters were fixed with meth-
anol and then stained with Giemsa stain (Sigma-Aldrich). 
The migrating and invading cell numbers were evaluated in 
six randomly selected fields across three independent experi-
ments under a light microscope (Zeiss Axio Imager A1, Jena, 
Germany) at 200× magnification.
In Vitro Cell Wound Healing Assay
Lung cancer cells were seeded on the Ibidi Culture-
Insert system (Applied BioPhysics, Inc., Troy, NY) for 12 
hours. Photographs were taken at the same position in the cell-
free gap insert under a light microscope (Zeiss Axio Imager 
A1) at 100× magnification at the 0-hour and 24-hour time 
points. The wound closure was analyzed using ImageJ soft-
ware, and the closure percentage was calculated as follows: 
wound closure (%) = [area of initial wound scratch − area after 
cell migration/area of initial wound scratch] × 100%.
Immunofluorescence and Confocal Microscopy 
Lung cancer cells (1 × 103 cells) cultured on glass cov-
erslips in a six-well culture plate were separately treated with 
either a scrambled control siRNA or an ACTN4-targeting 
siRNA for 24 hours. The cultured cells were washed, fixed 
with 4% paraformaldehyde (prewarmed to 37°C), and per-
meabilized with 0.1% Triton X-100. The prepared cells were 
incubated with a primary rabbit anti-ACTN4 immunoglobu-
lin G (IgG; 1:200; Epitomics). After washing, the cells were 
incubated with secondary goat anti-rabbit IgG antibody con-
jugated to Alexa Fluor594 (1:1000; Invitrogen). To detect the 
nuclei and actin filaments, the cells were stained with Hoechst 
33258 (Sigma-Aldrich) and phalloidin-iFluor 488 conju-
gate (1:1000; AAT Bioquest, Sunnyvale, CA). The immuno-
fluorescent cells were examined using a scanning confocal 
microscope (FV-1000; Olympus, Hamburg, Germany) or a 
fluorescence microscope (Zeiss Axio Imager A1).
Collection of Clinical Samples
The samples of tissue (n = 84) and plasma (n = 185) of 
patients with lung cancer were provided by the Tissue Bank 
of National Cheng Kung University (NCKU) Hospital, and 
plasma samples from an independent cohort of lung cancer 
patients (n = 145) was obtained from the Kaohsing Veterans 
General Hospital (KVGH). The plasma samples of healthy 
controls (n = 147) with no history of cancer were collected 
from the Health Examination Center of the NCKU Hospital. 
The collection procedure of clinical samples from the lung 
cancer patients and healthy controls complied with the regula-
tions of and was approved by Ethics Committee of the NCKU 
Hospital (Reference Code: ER-100-059, March, 25, 2011). 
All participants gave their informed consent to participate in 
this research study and signed the consent forms before par-
ticipating in this research.
Tissue Microarray
The immunohistochemistry of each tissue specimen 
was examined in duplicate by sampling tumor tissue cores 
and 4-μm-thick paraffin-embedded sections from the Tissue 
Bank of NCKU Hospital. The procedures were performed 
according to the Bond-Max automated immunohistochem-
istry staining protocol (Leica Biosystems Newcastle Ltd., 
Newcastle, UK). A rabbit monoclonal anti-ACTN4 IgG 
(1:250; Epitomics) was used as the primary antibody, and a 
mouse anti-rabbit IgG conjugated to HRP was used as the sec-
ondary antibody (Sigma-Aldrich). The signal was developed 
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with the chromogen 3, 3′-diaminobenzidene (Sigma-Aldrich). 
Counterstaining was carried out with hematoxylin. Image 
analysis of the ACTN4-positive cells was further quantified 
using the TissueFaxs microscopy system with the HistoQuest 
software module (TissueGnostics, Vienna, Austria).
Enzyme-Linked Immunosorbent Assay
Microtiter plates were labeled with a mouse monoclo-
nal anti-ACTN4 IgG (1:100; Abnova, Walnut, CA), washed, 
and blocked; thereafter, all of the plasma samples were loaded 
into the prepared microtiter plates. A rabbit polyclonal anti-
ACTN4 IgG (1:50; Proteintech, Chicago, IL) was added into 
each well. The bound rabbit polyclonal anti-ACTN4 IgG 
was detected using diluted anti-Rabbit IgG (1:6000; Sigma-
Aldrich) conjugated to HRP. The development was performed 
by SureBlue Reserve TMB Microwell HRP Substrate and 
Stop Solution (KPL, Gaithersburg, MD). The absorbance was 
read on a microplate photometer at 450 nm (Multiskan EX 
microplate reader).
Statistical Analysis
All the data were expressed as the mean ± standard devi-
ation (SD). The Mann–Whitney U and Kruskal–Wallis H tests 
were used to evaluate the differences in nonparametric groups. 
Analysis of variance and t tests were used to evaluate the dif-
ferences in parametric groups. A value of p < 0.05 was con-
sidered to be statistically significant. All the above measures 
and the receiver operating characteristic (ROC) curves were 
determined using SPSS software (SPSS 18.0, Chicago, IL).
RESULTS
Differential Expression and Secretion of 
ACTN4 Protein in CL1-0 and CL1-5 Cells
The CL1-5 cells have a relatively higher invasive abil-
ity than the CL1-0 cells after Matrigel invasion selection.7 
ACTN4 protein was reported to be one candidate factor 
that was associated with the invasive ability of the CL1-5 
cell line; a differential expression and secretion of approxi-
mately twofold had been observed in CL1-5 cells relative 
to CL1-0 cells in previous label-free mass spectrometry–
based proteomic quantification analyses from this labora-
tory.8–10 A relative intensity quantification of the Western 
blot data showed that the level of ACTN4 protein in the 
CE of CL1-5 cells was threefold greater than that in CL1-0 
cells, and the level of ACTN4 protein in the CM of CL1-5 
cells was sixfold greater than that in CL1-0 cells (Fig. 1A 
and B). These data indicate a differential expression and 
secretion of ACTN4 protein in CL1-0 and CL1-5 cells.
Functional Role of ACTN4 Protein 
in CL1-5 and CL1-0 Cells
Two pools of different siRNA sequences were individ-
ually transfected and investigated for ACTN4 knockdown 
in CL1-5 cells to generate fewer off-target effects. Figure 
2A shows the effects of ACTN4 knockdown in CL1-5 cells. 
CL1-5 cells treated with ACTN4 siRNA exhibited only 20% 
and 15% of the control levels of ACTN4 expression in the 
CEs and CMs, respectively. To evaluate the CL1-5 cells 
after treatment with ACTN4 siRNA or scrambled control 
for cell migration and invasion abilities, the cell viability 
(MTT assay) and cell proliferation (BrdU assay) experi-
ments were performed in parallel with transwell, Matrigel, 
and wound-healing assays. Both MTT reduction assay and 
BrdU incorporation assay mimicked and reinforced the 
viability and proliferation ability of CL1-5 cells. The data 
showed the slope of absorbance increasing, and there were 
no significant differences between the CL1-5 cells treated 
with ACTN4 siRNA or scrambled control over time up to 
72 hours (Fig. 2B and C). Meanwhile, CL1-5 cells treated 
with the ACTN4 siRNA or scrambled control were tested in 
transwell (Fig. 2D), Matrigel (Fig. 2E), and wound-healing 
assays (Fig. 2F). The data for the transwell and Matrigel 
assays revealed that the cell number of migrating and inva-
sive CL1-5 cells was considerably decreased (approximately 
75%) in 48 hours when the cells were treated with ACTN4 
siRNA. In addition, the wound-healing assay showed a 
wound closure of 84.5% for the CL1-5 cells treated with 
scrambled control, compared with 35% for the CL1-5 cells 
treated with the ACTN4 siRNA (Fig. 2F). In addition, A549 
lung cancer cells also showed similar data and behavior 
(Supplementary Fig. S1A–F). In divergent experiments, 
the effects of ACTN4 overexpression in CL1-0 cells were 
evaluated. CL1-0 cells were transfected with ACTN4 DNA 
vector. After 48 hours, the level of ACTN4 protein in the 
CL1-0 cells was significantly increased (approximately 
sevenfold) and was greater than that in CL1-0 cells trans-
fected with control vector (Fig. 2G). The functional role 
of ACTN4 protein in CL1-0 cells was also studied, CL1-0 
cells transfected with ACTN4 expression vector and control 
vector were tested in transwell (Fig. 2H) and Matrigel (Fig. 
2I) assays. The data for the transwell and Matrigel assays 
revealed that the numbers of migrating and invasive CL1-0 
cells transfected with ACTN4 expression vector were con-
siderably increased, approximately 2.5- to 3-fold, relative to 
cells transfected with control vector, in 48 hours. These data 
suggested that the ACTN4 protein participates in lung can-
cer cell mobility.
Subcellular Distribution of ACTN4 
in CL1-0 and CL1-5 Cells
To define the precise localization and function of 
ACTN4 in CL1-0 and CL1-5 cells, the subcellular dis-
tribution of ACTN4 protein was examined by immuno-
localization, combined with ACTN4 siRNA and ACTN4 
overexpression in CL1-0 cells. The cellular morphology of 
CL1-5 cells treated with scrambled control was examined 
microscopically; most of these had a protruding mesen-
chymal- or spindle-like morphology (approximately 86%), 
and a small population (14%) had a globular morphology 
(Fig. 3A, upper panel). Notably, the morphologyof CL1-5 
cells independently treated with different pools of ACTN4 
siRNA sequences was altered; these CL1-5 cells predomi-
nantly had a globular shape (85%), and only a small pro-
portion (approximately 15%) showed mesenchymal- or 
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spindle-like forms (Fig. 3A, middle and low panels). In 
addition, typical CL1-0 cells mainly showed epithelial-like 
morphology (Fig. 3B, upper panel). Particularly, the CL1-0 
cells (approximately 68%) showed an elongated mesenchy-
mal- or CL1-5-like morphology when they were transfected 
with ACTN4 DNA vector (Fig. 3B, lower panel). Under 
confocal immunofluorescence microscopy, CL1-0 cells 
showed an epithelial-like morphology and some exten-
sions or small pseudopod extensions from cell membranes 
(Fig. 3C, left column). CL1-5 cells treated with scrambled 
control had ruffled cell membranes and elongations at the 
front of each cell, forming a pseudopod structure (Fig. 3C, 
middle column). In contrast, CL1-5 cells treated with the 
ACTN4 siRNA showed a globular shape, and the ACTN4 
and actin proteins were retracted from the edge of the 
CL1-5 cell membrane and condensed in a globular shape 
(Fig. 3C, right column).
Correlation between ACTN4 Protein 
Expression and Lung Cancer Stages 
by Immunohistochemistry
The NSCLC cases were included in the analyses of 
the T, N, and M descriptors and the subsequent analysis 
of TNM subsets and stage groupings.19 The T staging is 
determined by the size of primary tumor in long axis, the 
N classification defines the degree of spread to regional 
lymph nodes, and the M staging defines the presence of 
metastases beyond regional lymph nodes. The overall stage 
( I, II, III, and IV) of the NSCLC is determined by the com-
bination of T, N, and M grades. ACTN4 expression was 
quantified by TMA. To assess the results of immunohisto-
chemistry for ACTN4 expression, the immunoreaction was 
considered to be present, showing ACTN4 immunoreactiv-
ity intensity for the surgical tumor cell specimen and the 
adjacent normal tissue as the standard. The representative 
FIGURE 1.  Differential expression and secretion of ACTN4 protein in CL1-0 and CL1-5 cells. A, Western blots of ACTN4 protein 
expression in cell extracts (CE) and ACTN4 secretion into conditioned media (CM) from the CL1-0 and CL1-5 lung cancer cells. 
B, The quantification of relative intensity of ACTN4 protein in the CE and CM of the CL1-5 and CL1-0 lung cancer cells. The 
signal intensity of Western blotting was normalized to the intensity of the CL1-0 ACTN4 protein. Tubulin and phosphoglycerate 
mutase 1 (PGAM1) were used as loading controls for CE and CM, respectively.
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FIGURE 2.  The effects of ACTN4 protein on cell migration and invasiveness in CL1-5 cells. A, The Western blot data and relative 
intensity quantification of ACTN4 protein in cell extracts and conditioned media of the lung cancer CL1-5 cells after treating 
different pools of ACTN4 siRNA. Tubulin, actin, and PGAM1 were used as loading controls for cell extracts and conditioned 
media. The signal intensities of Western blotting were normalized to the intensity of the CL1-5 cells treated with scrambled 
control. B, MTT cell viability assay and (C) BrdU cell proliferation assay of CL1-5 cells treated with ACTN4 scrambled control or 
ACTN4 siRNA. Mann–Whitney U tests were carried out for each interval (p < 0.05). The results of (D) the transwell migration 
assay, (E) the Matrigel invasion assay, and (F) the wound healing assay of CL1-5 cells treated with scrambled control or ACTN4 
siRNA. G, Western blots and relative intensity quantification of differential expression of ACTN4 protein between CL1-0 cells 
transfected with control vector or ACTN4 DNA vectors. The signal intensity of Western blotting was normalized to the intensity 
of the CL1-0 cells transfected with control vector. The results of (H) the transwell migration assay and (I) the Matrigel invasion 
assay of CL1-0 cells transfected with control vector or ACTN4 DNA vectors. The quantification values of the transwell migration 
assays and Matrigel invasion assays are expressed as the mean ± SD values from triplicate experiments, and the cell numbers were 
calculated from six random fields under a light microscope at 100× magnification. The wound-healing assay was quantified 
using ImageJ software. The gray line indicates the initial wound scratch boundary, and the black line indicates the boundary of 
cell migration after 24 hours. The quantification of the wound-healing assay is provided as the mean ± SD values of triplicate 
experiments, and a Mann–Whitney U test was performed (p < 0.05).
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results of immunohistochemistry showed higher expression 
of ACTN4 in the different stages of tumor compared with 
the expression in adjacent normal tissues(Fig. 4A). The col-
lected number of tissue samples were 30, 19, 27, and 8 for 
stages I, II, III, and IV, respectively. The distribution of age 
was from 21 to 79 years. Obviously, the number of sample 
of NSCLC stage IV is less than the numbers for the other 
three stages because the treatment options for stage IV of 
NSCLC include cytotoxic chemotherapy and radiation; in 
contrast, surgery is generally used in selective cases for 
symptom palliation. The quantitation of ACTN4 expres-
sion from the collected TMA samples (Supplementary Fig. 
S2) is shown by a scattergram of the immunohistochemi-
cal localization of ACTN4 protein expression in NSCLC 
patients (Fig. 4B) (i). The correlation between histological 
ACTN4 expression and clinicopathological stage is shown 
in Table 1. There were no significant differences in ACTN4 
expression between the groups with regard to patient 
age and gender. In comparison, NSCLC tumors showing 
ACTN4 protein were strongly stained and tended toward 
apparent ACTN4 protein overexpression, with the highest 
staining at different NSCLC classifications, such as overall 
stages III, T4, and N2. Although the data in each group of 
different classifications was divergence and partial overlap 
for clinical samples; notably, the mean of immunohisto-
chemistry ACTN4 expression intensity showed significant 
difference in the beginning between adjacent normal and 
overall stage I. On further analysis, the paired test for the 
adjacent normal versus cancer tissues also yielded signifi-
cantly different results. The ACTN4 expression intensity 
determined by immunohistochemistry was significantly 
increased from overall stage II to stage III, then declin-
ing in stage IV; the physiological and significant role of 
ACTN4 in the NSCLC staging process needs further inves-
tigation. An ROC was plotted for the tissue ACTN4 staining 
of cancer tissue versus normal adjacent tissue, and the area 
under the curve (AUC) was 0.736 (p < 0.001; Fig, 4B, (ii)).
Correlation between Plasma ACTN4 Protein 
Concentration and Lung Cancer Stages by ELISA
Plasma was obtained from two cohorts of lung adeno-
carcinoma patients from NCKU (185 samples; 96, 30, 45, 
and 14 for stages I, II, III, and IV, respectively) and KVGH 
(145 samples; 40, 39, 42, and 24 for stages I, II, III, and IV, 
respectively) and from 147 healthy donors. The scattergrams 
of plasma ACTN4 protein concentration in healthy controls 
and lung cancer patients from NCKU and KVGH are shown 
in Figure 4C (i) and Figure 4D (ii). The ELISA results showed 
that the concentration of ACTN4 protein in healthy plasma 
was 3.41 μg/ml and 3.50 μg/ml (p < 0.05) for the samples 
from NCKU and KVGH, respectively. There were no sig-
nificant differences between the ACTN4 levels with age and 
gender in healthy controls. The correlation between ACTN4 
protein expression and the clinical plasma levels for lung 
adenocarcinoma from NCKU and KVGH samples is listed in 
Tables 2 and 3. The samples of both cohorts showed statisti-
cally significant differences in plasma ACTN4 protein concen-
tration between healthy controls and lung cancer patients (p < 
0.001). The plasma ACTN4 concentration was maintained at 
approximately 8 to 10 μg/ml in stage I of NSCLC and across 
the overall lung cancer process. It is a conspicuous increase of 
approximately 2.5 to 3-folds over healthy control plasma (p < 
0.001). However, on further analysis, ACTN4 protein concen-
tration did not show significant difference among the different 
overall stages of lung cancer during the cancer development 
process. The ROCs were plotted for the plasma ACTN4 pro-
tein concentration in healthy controls versus cancer patients, 
and the areas under the ROC curves were 0.828 and 0.909 
for the samples from NCKU and KVHP, respectively (p < 
0.001; Fig. 4C (ii) and Fig. 4D (ii)).
FIGURE 2.  (Continued)
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FIGURE 3.  Subcellular function and distribution of ACTN4 in CL1-0 and CL1-5 cells. A, Photomicrographs of CL1-5 cells treated 
with ACTN4 scrambled control or different pools of ACTN4 siRNA. The thin arrows indicate a typical morphology of CL1-5 cells 
treated with the ACTN4 scrambled control; these cells show mesenchymal-like morphology (upper panels). The thick arrows 
indicate a typical morphology of CL1-5 cells treated with the ACTN4 siRNA; these cells show primarily globular cells (lower pan-
els). The scale bar represents 100 μm. Quantification of the numbers of mesenchymal-like CL1-5 cells treated with the ACTN4 
scrambled control or the ACTN4 siRNA. The data are provided as the mean ± SD and were calculated from six random areas. 
B, Fluorescent photomicrographs of CL1-0 cells transfected with control vector and ACTN4 DNA vector and stained with actin. 
The typical morphology of CL1-0 cells is a typical epithelial-like shape (upper panels) and the typical CL1-0 cells transfected with 
ACTN4 DNA vector had elongated mesenchymal- or CL1-5-like morphology (lower panels). Quantification of the epithelial-like 
CL1-0 cells transfected with control vector or ACTN4 DNA vectors is provided as the mean ± SD from six random areas.  
C, High-magnification confocal immunofluorescence microscopy photographs. The CL1-0 cells showed an epithelial-like morphology 
with short extended pseudopods at the cell membranes (panels at left column). Two typical cell morphologies of CL1-5 cells 
treated with the ACTN4 scrambled control (panels at middle column) and the ACTN4 siRNA (panels at right column). The scale 
bar represents 10 μm. Actin was labeled with phalloidin-iFluor 488 (green color), the nuclei were labeled with Hoechst 33258 
(blue color), and ACTN4 was detected using a goat anti-rabbit IgG conjugated to Alexa Fluor 594 (red color).
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DISCUSSION
The ability of cancer cells to migrate and invade 
is critical determinant in the spread of cancer from the 
tissue of origin and affects the subsequent implanta-
tion into other organs.20 Factors that enhance cancer cell 
migration and invasion include many proteins involved 
in the remodeling of the actin cytoskeleton and several 
associated proteins,21 such as Rac and Cdc42 proteins, 
which are members of the Rho guanosine triphosphatase 
(GTPase) superfamily,22 and actin-binding proteins, such 
as fascin23 and ACTN4.14,24 In this study, we determined 
that ACTN4 protein is highly expressed and secreted in 
the highly invasive CL1-5 cells. ACTN4 protein also par-
ticipates in migration in different cancers, such as blad-
der, colorectal, and ovarian cancers.25–30 However, what is 
the role of ACTN4 in cancer cell metastasis? In this study, 
we report that ACTN4 protein knockdown suppresses 
CL1-5 migration and invasion because the morphology 
of CL1-5 was altered from mesenchymal-like to globu-
lar shape. In addition, ACTN4 overexpression in CL1-0 
cells caused the cell morphology to be changed from the 
epithelial-like to mesenchymal-like shape. It is believed 
FIGURE 3.  (Continued)
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FIGURE 4.  The levels of ACTN4 
in cancerous tissues and plasma 
samples of lung cancer patients. A, 
Representative images of the ACTN4 
protein immunoreactivity of tissues at 
different stages of lung cancer, under 
a light microscope (200× magnifica-
tion). The negative control samples 
were not incubated with primary rab-
bit anti-ACTN4 IgG. B, Scattergram 
of (i) immunohistochemical study 
of ACTN4 protein expression by 
diaminobenzidine intensity of adja-
cent normal and total lung cancer 
clinicopathological tissues, and (ii) 
the receiver operating characteristic 
curve was plotted for the ACTN4 
staining of cancer tissues versus 
the normal adjacent tissues. Both 
scattergrams (i) in (C) and (D) were 
plotted for plasma ACTN4 protein 
concentration in the healthy controls 
and lung cancer patients from NCKU 
and KVGP samples, respectively. The 
red lines indicate the means of the 
ACTN4 concentration in each group. 
Both receiver operating characteristic 
curves (ii) in (C) and (D) were plotted 
for the plasma ACTN4 protein from 
the cancer patients versus the healthy 
controls from NCKU and KVGP 
samples, respectively (p < 0.001).
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that mesenchymal-like cell is certain to form pseudo-
pods and migrate.21 In this study, ACTN4 participated in 
regulating the dynamic assembly and disassembly of the 
pseudopod structure. The polarity and directed migration 
of such cells is determined by the assembly, extension, 
and stabilization of a pseudopod.31 ACTN4 knockdown 
in keratinocytes has shown that the keratinocytes lack 
polarity and have 25% increased focal contact area.32 In 
the regulation of colorectal cancer metastasis, the cad-
herin/catenin system mediates cell–cell adhesion and 
acts as an invasion suppressor of epithelial malignancies. 
On inhibition of E-cadherin expression, ACTN4 can bind 
with β-catenin in the membrane protrusions of DLD-1 
cells. This study shows that ACTN4 takes part in the 
regulation of cell–cell adhesion through dynamic binding 
to β-catenin from cell adhesion complex and mediates 
cell invasion and metastasis.33 Therefore, these data may 
explain the histochemistry staining that showed the high-
est intensity of ACTN4 protein expression in stage III 
of lung cancer tissue; NSCLC cells overexpress ACTN4 
protein, which regulates the loss of cell adhesion through 
the competition with cadherin/catenin system; NSCLC 
cells then develop the ability to leave the original lesion 
and migrate enabling distant metastasis (M stage). In 
MRC-5 lung f ibroblast cells, subcellular ACTN4 proteins 
were localized in the cytoplasm and along actin stress 
f ibers.14 ACTN4 is an actin-binding protein that is dif-
ferently localized in moving structures, such as ruffles, 
lamellipodia, and f ilopodia,31,34 but not in the adherens 
junctions.33 The expression level of ACTN4 was signif i-
cantly increased in CL1-5 cells (Fig. 1 and 2), and the 
increased expression of ACTN4 dramatically changed the 
cell morphology and motility of lung cancer cells (Fig. 
2A and 3A). Moreover, during cancer metastasis, abnor-
mal tumor-derived exosomes were found to be secreted.35 
Tumor-derived exosomes are enclosed cytosolic and 
membrane proteins derived from the parental cells, and 
these exosomes modulate the tumor microenvironment 
for cancer cell metastasis. The cytosolic molecules in 
exosomes include DNA,36 RNA,37 and protein.9 ACTN4 
was one of the candidate exosome proteins found in pre-
vious studies conducted in this laboratory and in this 
study. Thus, ACTN4 protein participates in migration of 
NSCLC cells and, after secretion, modulates the microen-
vironment of cancer cells for cancer development.
Interestingly, from a comparison of ACTN4 expres-
sion as found in immunohistochemical data and plasma 
ELISA data, it can be inferred that ACTN4 protein 
expression varies with the clinical stage of lung cancer, 
with the highest staining at stage III and lower expression 
at stage IV; however, ACTN4 protein concentration in the 
plasma was maintained constant at approximately 8–10 
μg/ml. It is not clear why ACTN4 protein is secreted and 
maintained across the overall lung cancer process. The 
function of ACTN4 has however been previously found; 
ACTN4 affects the expression of matrix metalloprotein-
ase gene 38 and ACTN4 is upregulated by three-dimen-
sional collagen culture conditions, leading to increased 
invasion and motility of ovarian cancer cells.39 Previous 
research showed that matrix metalloproteinase-9 can 
degrade and reconstitute the ECM to facilitate tumor cell 
migration and invasion.40,41 All these results suggest that 
ACTN4 enhances or activates other metastatsis-associ-
ated proteins and regulates cell mobility in lung cancer.
In summary, this approach is based on the pre-
liminary identification of the expressed and secreted pro-
teins of lung cancer CL1-0 and CL1-5 cells by liquid 
chromatography–tandem mass spectrometry and the sub-
sequent functional characterization of candidate ACTN4 
protein. We also showed that ACTN4 protein is a mobility-
related protein that influences the filopodia or lamellipo-
dia structures in lung cancer CL1-5 cells. The evaluation 
FIGURE 4.  (Continued)
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results of clinical samples suggest that ACTN4 protein 
is a potential indicator to discriminate between plasma 
samples of healthy controls and NSCLC patients.
TABLE 2.  Correlation between ACTN4 Protein Expression and 
the Clinical Plasma Levels in Lung Adenocarcinoma Using an 
ELISA Experiment. The Cancer Plasma Samples Were from NCKU
Variable
No. of  
Patients
ACTN4 Level  
(μg/ml) (Mean ± SD)
p  
Valuesa
Healthy: Total 147
Age, years 21–49 25 4.09 ± 2.55 0.083
50–59 38 3.42 ± 1.98
60–69 41 2.84 ± 1.70
70–79 33 3.26 ± 1.83
≥80 10 4.49 ± 2.57
Gender Male 71 3.30 ± 2.15 0.801
Female 76 3.51 ± 2.44
Patients: Total 185
Age, years 21–49 16 8.50 ± 6.58 0.583
50–59 63 8.57 ± 5.23
60–69 61 8.54 ± 6.80
70–79 41 13.09 ± 18.07
≥80 4 15.89 ± 14.91
Gender Male 85 10.58 ± 9.62 0.028c
Female 100 8.97 ± 10.91
Healthy vs. patients Healthy 147 3.52 ± 2.35 <0.001c
Patients 185 9.71 ± 10.34
Overall stage I  96 10.51 ± 13.35 0.679
II  30 8.24 ± 5.12
III  45 9.11 ± 5.78
IV 14 9.28 ± 5.17
Healthy vs. Stage I Healthy 147 3.41 ± 2.30 <0.001
Stage I 96 10.51 ± 13.35
Stage I vs. Stage II Stage I 96 10.51 ± 13.35 0.652
Stage II 30 8.24 ± 5.12
Stage II vs. Stage III Stage II 30 8.24 ± 5.12 0.344
Stage III 45 9.11 ± 5.78
Stage III vs.  
Stage IV
Stage III 45 9.11 ± 5.78 0.347
Stage IV 14 9.28 ± 5.17
T stage group T1 90 9.17 ± 8.93 0.527
T2 66 10.77 ± 13.44
T3 12 10.02 ± 6.55
T4 16 8.40 ± 3.83
N stage N0 108 10.64 ± 12.71 0.330
N1  26 6.26 ± 3.84
N2  46 9.44 ± 5.86
N3  4 9.24 ± 3.44
M stage M0  142 9.65 ± 11.00 0.667
M1  13 9.37 ± 8.06
aThe Kolmogorov–Smirnov test was examined for the normality of collected data 
distribution.
Nonparametric statistics
Age: Kruskal–Wallis H
Sex: Mann–Whitney U
Healthy controls vs. patients: Mann–Whitney U
Stage: Kruskal–Wallis H
Each stage vs. each stage: Mann–Whitney U
Tumor size (T): Kruskal–Wallis H
Lymph node metastasis (N): Kruskal–Wallis H
Distant metastasis (M): Mann–Whitney U
cp < 0.05 is considered to be a significant difference.
TABLE 1.  Correlation between ACTN4 Protein Expression 
and Clinical Pathologic Features of Lung Adenocarcinoma 
Using Image Analysis; Quantification of ACTN4-Positive 
Tissue Microarray
Variable
No. of  
Patients
Gray Values  
(Mean ± SD)
p 
Valuesa
Total: 84 patients
Age, years 21–49 7 74.94 ± 15.01 0.383
50–59 28 94.7 ± 31.7
60–69 32 93.9 ± 30.91
70–79 17 88.53 ± 22.01
Gender Male 33 89.63 ± 20.32 0.879
Female 51 92.71 ± 33.17
Overall stage I 30 81.2 ± 23.66 <0.001
II 19 83.76 ± 16.46
III 27 113.58 ± 31.36
IV 8 74.02 ± 16.02
Adjacent normal  
vs. Stage I
Adjacent 
normal
31 71.70 ± 11.91 <0.002
Stage I 30 81.2 ± 23.66
Stage I vs. Stage II Stage I 30 81.2 ± 23.66 0.545
Stage II 19 83.76 ± 16.46
Stage II vs. Stage III Stage II 19 83.76 ± 16.46 <0.003
Stage III 27 113.58 ± 31.36
Stage III vs. Stage IV Stage III 27 113.58 ± 31.36 <0.00
Stage IV 8 74.02 ± 16.02
Adjacent normal  
vs. Cancer
Adjacent 
normal
31 71.70 ± 11.91 <0.001
Cancer 31 87.07 ± 30.36
T stage group T1 25 91.63 ± 28.43 0.326
T2 41 87.46 ± 27.97
T3 8 99.01 ± 19.09
T4 10 101.75 ± 37.99
N stage N0 36 82.74 ± 22.19 0.007
N1 20 89.03 ± 32.36
N2 27 105.45 ± 29.74
N3 1 79.61
M stage M0 74 92.53 ± 28.80 0.094
M1 7 73.74 ± 16.15
aThe Kolmogorov–Smirnov test was examined for the normality of collected data 
distribution.
(1) Nonparametric statistics
Age: Kruskal–Wallis H
Sex: Mann–Whitney U
Adjacent normal vs. stage I: Mann–Whitney U
Each stage vs. each stage: Mann–Whitney U
Adjacent normal vs. cancer: Wilcoxon matched–pairs test
Tumor size (T): Kruskal–Wallis H
Tumor size group: Kruskal–Wallis H
Lymph node metastasis (N): Kruskal–Wallis H
Lymph node metastasis group: Mann–Whitney U
(2) Parametric statistics
Stage: One-way analysis of variance
Distant metastasis (M): t test
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